DataMeds AI, Inc. (MEDS)
CIK 2030763 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 3.1M shares as of Aug 17, 2026 (10-Q). Share count fell from 125.7M to 3.1M between May 19, 2026 and Aug 17, 2026, a pattern consistent with a reverse split (roughly 1-for-41); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
Warrants outstanding: 1.1M underlying shares, as reported Jan 20, 2026 (10-Q).
Reported exercise price: $0.01 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $1.3M as of Mar 31, 2026.
Rough fully diluted estimate: 4.2M = 3.1M O/S + 1.1M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| New Convertible Notes | $20.3M | — | not tagged | — | — |
| New Convertible Promissory Notes | $9.6M | $20.3M | not tagged | — | — |
| Original Convertible Promissory Notes | $9.6M | — | not tagged | — | — |
| Secured Convertible Promissory Notes | $8.1M | — | not tagged | — | — |
| Convertible Promissory Notes | $1.5M | — | not tagged | — | — |
Notes exactly as the company dimensioned them in its 10-Q filed Aug 17, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 3.1M | Aug 17, 2026 |
| + Warrants (aggregate, as tagged) (if exercised) | 1.1M | Jan 20, 2026 |
| Fully diluted estimate | 4.2M | +35.8% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $310.5Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 9 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full MEDS workspace